Scientific Evaluation of the Safety and Efficacy of Herbal and Non Herbal Formulations in Mitigating Hair Fall, Promoting Hair Growth, and Preventing Premature Hair Graying.
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Hair Fall and Pre-mature Graying
- Sponsor
- NovoBliss Research Pvt Ltd
- Enrollment
- 99
- Primary Endpoint
- change in GSS score by using CASLite Nova
- Status
- Not yet recruiting
- Last Updated
- last year
Overview
Brief Summary
This is proof-of-science, prospective, interventional, three-arm, double-blind, randomized, safety and efficacy real world evidence study of herbal and non herbal formulations in healthy human subjects having complaint of hair fall and pre-mature graying.
Detailed Description
Considering the clinical safety, efficacy study a sufficient number 99 subjects (33 subject/arm) will be enrolled to 90 subjects (30 subject/arm) completed the study. In each arm, fifteen (15) participants per group will be recruited, with one group consisting of individuals experiencing mild to moderate Androgenetic Alopecia (AGA) class 1, 2, 3, while the other group will comprise fifteen (15) healthy subjects with symptoms of hair loss and premature graying. The potential subjects will be screened as per the inclusion \& exclusion criteria only after obtaining written informed consent from the subjects. The adult female/male subjects will be instructed to visit the facility as per the below visits. * Visit 01 (Day -04): Screening, Tattoo creation, Hair Growth Rate measurement * Visit 02 (Day 01): Enrolment, Hair Growth Rate measurement, All evaluations * Visit 03 (Day 45 (±2 days)): Treatment Phase * Visit 04 (Day 87 (±2 days)): Treatment Phase, Tattoo creation, Hair Growth Rate measurement Visit 05 (Day 90 (3 days from visit 04): Hair Growth Rate measurement, All evaluations * Visit 06: (Day 120 (±2 days)): End of Treatment Phase, All evaluations
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age: 18 to 55 years and above (both inclusive) at the time of consent.
- •Sex: Males and non-pregnant/non-lactating females (preferably equal number of males and females).
- •Females of childbearing potential must have a self-reported negative urine pregnancy.
- •Subject is in good general health as determined by the Investigator on the basis of medical history.
- •Female with 40-50 counts and male with 25 -30 counts of hair fall at screening.
- •Subject having AGA and premature Gray hair at a time of screening.
- •Subject having premature gray hair at a time of screening.
- •Subject with pro-claimed nonpathological thinning of hair.
- •Subject is able to remain on stable doses of contraceptive or replacement hormonal therapy, including no therapy, 6 weeks prior to and for the duration of the study.
- •If the subject is of childbearing potential, is practicing and agrees to maintain an established method of birth control (IUD, hormonal implant device/injection, regular use of birth control pills or patch, diaphragm, condoms with spermicide or sponge with spermicidal jelly, cream or foam, partner vasectomy or abstinence). Females will beconsidered as non-childbearing potential if they are surgically sterile, have been post menopausal for at least 1 year or have had a tubal ligation.
Exclusion Criteria
- •Subject have history of severe hair fall due to any clinically significant problems like anaemia, thyroid problems.
- •Subject have history of any dermatological condition of the scalp other than hair loss and dandruff.
- •Subject have history of any prior hair growth procedures (e.g. hair transplant or laser).
- •Subject who had taken topical treatment of hair loss for at least 4 weeks.
- •Subject who had taken any systemic treatment for at least 3 months.
- •History of alcohol or drug addiction.
- •Subject having history or resent condition of irritated or visibly inflamed scalp or severe scalp disease.
- •Subject having history or present condition of an allergic response to any cosmetic products, any other condition which could warrant exclusion from the study.
- •Pregnant or breast feeding or planning to become pregnant during the study period.
- •History of chronic illness which may influence the cutaneous state.
Outcomes
Primary Outcomes
change in GSS score by using CASLite Nova
Time Frame: Baseline before usage of the test products on Day 01 and after usage of the test products on Day 120 (+2 days)
To assess the effectiveness of the test products in terms of change in GSS score
change in hair density by using CASLite Nova
Time Frame: Baseline before usage of test product on Day 01 and after usage of the test products on Day 45 , Day 90 and Day 120
To assess the effectiveness of the test products in terms of hair density by using CASLite Nova.
change in hair fall by using 60 second hair combing test.
Time Frame: Baseline before usage of the test products (04 days before Day 01) and after usage of the test on Day 45, Day 90 and Day 120.
To assess the effectiveness of the test products in terms of change in hair fall by using 60 second hair combing test.
change in scalp skin hydration by using Corneometer CM 825
Time Frame: Baseline before usage of the test products on Day 01 and after usage of the test products on Day 45, Day 90 and Day 120
To assess the effectiveness of the test products in terms of change in scalp skin hydration
change in hair strength by using hair pull test.
Time Frame: Baseline before usage of the test products (04 days before Day 01) and after usage of the test on Day 45, Day 90 and Day 120
To assess the effectiveness of the test products in terms of change in hair strength by using hair pull test
change in Anagen: Telogen (A: T) Ratio by using Hair Pluck Test by dermatologist.
Time Frame: Baseline before usage of the test products on Day 01 and after usage of the test products on Day 120
To assess the effectiveness of the test products in terms of change in Anagen: Telogen (A: T) Ratio
change in hair thickness by using CASLite Nova
Time Frame: Baseline before usage of test product on Day 01 and after usage of the test products on Day 45 , Day 90 and Day 120
To assess the effectiveness of the test products in terms of change in hair thickness by using CASLite Nova.
change in hair growth rate by using CASLite Nova
Time Frame: Baseline before usage of the test products on Day 01 and after usage of the test products on Day 45 , Day 90 and Day 120 .
To assess the effectiveness of the test products in terms of change in hair growth rate by using CASLite Nova
change in ASFS by using ASFS scoring scale.
Time Frame: Baseline before usage of the test products on Day 01 and after usage of the test products on Day 45 (+2 days), Day 90 (3 days from the visit 04) and Day 120 (+2 days)
To assess the effectiveness of the test products in terms of change in ASFS where 0-10 scale (0 means no flakes and 10 means heavy flaking)
Secondary Outcomes
- change in lipid deposition of the hair by using XRF method(Baseline on Day 1 and post application of the test products at 120 Days)
- change in damage repair of the hair by using SEM analysis(Baseline on Day 1 and post application of the test products at 120 Days)
- change in general appearance of hair(Baseline before usage of the test products on Day 01 and after usage of the test products on Day 45, Day 90 and Day 120.)
- change in general appearance of scalp.(Baseline before usage of the test products on Day 01 and after usage of the test products on Day 45 , Day 90 and Day 120.)
- change in digital photographs of the head crown Nikon digital camera D3300(Before usage of the test products on Day 01 and after usage of the test products on Day 45 , Day 90 and Day 120.)
- change in products perception questionnaire by using 5-point Likert scale(Before usage of the test products on Day 01 and after usage of the test products on Day 45, Day 90 and Day 120)
- sensorial evaluation on the hair tress by 6 expert evaluation.(Baseline and post application of the test products on Day 1 at T 60 minutes)
- change in hair shine using glossymeter GL 200(Baseline and post application of the test products on Day 1 at T 60 minutes)